Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Title
Intervention Indication Therapeutic Area Year Actions
ASTX727 for acute myeloid leukaemia ASTX727 Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2022 View  |  Download
Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) – second line Brexucabtagene autoleucel (Tecartus; KTE-X19) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Blinatumomab (Blincyto) for First Relapsed/Refractory, B-precursor, Acute Lymphoblastic Leukaemia, in Children and Adolescents Blinatumomab (Blincyto) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Dasatinib (Sprycel) tablets for children with type II variation, philadelphia positive acute lymphoblastic leukaemia Dasatinib (Sprycel; BMS 354825; dasatinib monohydrate) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
JZP-458 for acute lymphoblastic leukaemia and lymphoblastic lymphoma JZP-458 (RC-P; Recombinant Erwinia asparaginase) Acute lymphoblastic leukaemia (ALL) , Lymphoblastic lymphoma (LBL) Haematological Cancer and Lymphomas 2020 View  |  Download
KTE-C19 for Relapsed/Refractory B-precursor Acute Lymphocytic Leukaemia in Adults Brexucabtagene autoleucel (Tecartus; KTE-X19) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications